Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

RNA-seq analysis of PRMT5-regulated genes in irradiated/non-irradiated LNCaP cells

ABSTRACT: RNA-seq analysis of PRMT5-regulated genes in irradiated/non-irradiated LNCaP cells

PROVIDER: PRJNA437575 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR6820620_1.fastq.gz	Fastqsanger.gz
	SRR6820620_2.fastq.gz	Fastqsanger.gz
	SRR6820621_1.fastq.gz	Fastqsanger.gz
	SRR6820621_2.fastq.gz	Fastqsanger.gz
	SRR6820622_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 24

Similar Datasets

RNA-seq analysis of PRMT5-regulated genes in irradiated/non-irradiated LNCaP cells

Project description:DNA Double-strand break (DSB) repair is critical for cell survival and genome integrity. Upon recognition of DSBs, repair proteins are transiently upregulated to facilitate repair through homologous recombination (HR) or non-homologous end joining (NHEJ). We present evidence that PRMT5 cooperates with pICln to function as a master epigenetic activator of DNA damage response (DDR) genes involved in HR, NHEJ, and G2 arrest (including RAD51, BRCA1, and BRCA2) to upregulate gene expression upon DNA damage. Contrary to the predominant role of PRMT5 as an epigenetic repressor, our results demonstrate that PRMT5 and pICln can activate gene expression, potentially independent of PRMT5’s obligate cofactor MEP50. Targeting PRMT5 or pICln hinders repair of DSBs in multiple cancer cell lines, and both PRMT5 and pICln expression positively correlates with DDR genes across 32 clinical cancer data sets. Thus, targeting PRMT5 or pICln may be explored in combination with radiation or chemotherapy for cancer treatment.

2019-12-05 | GSE111620 | GEO

shRNA-mediated knockdown of PRMT5 gene in LNCaP cells

Project description:We performed shRNA-mediated knockdown of PRMT5 in LNCaP cells via dox-inducible expression system. We sought to compare transcriptome with- and without PRMT5 knockdown across three biological replicates

2025-06-13 | GSE206111 | GEO

PRMT5 knockdown changes gene expression in prostate cancer cells

Project description:PRMT5 is the major type II protein arginine methyltransferase catalyzing the symmetric dimethylation of arginine. Recent reports have indicated that PRMT5 is overexpressed in multiple cancer types, including prostate. However, the exact contribution of PRMT5 to prostate tumorigenesis is unknown. To explore the functional role of PRMT5 in prostate cancer (PCa), we knocked down PRMT5 by lentiviral shRNAs in both AR-dependent LNCaP cells and AR-independent PC3 cells. Our data suggests that PRMT5 regulates PCa cell biology. To further identify PRMT5-regulated genes in PCa, we performed paired-end RNA-seq analysis in PC3 and LNCaP cells with or without PRMT5-knockdown.

2023-12-25 | GSE117596 | GEO

PRMT5 regulated transcriptome in prostate cancer cells

Project description:Compared to intensely studied DNA methylation, protein methylation is less studied. PRMT5 is the major type II protein arginine methyltransferase catalyzing the symmetric dimethylation of arginine. Recent reports have indicated that PRMT5 is overexpressed in multiple cancer types, including prostate. However, the exact contribution of PRMT5 to prostate tumorigenesis is unknown. To explore PRMT5 in prostate cancer (PCa) therapeutically, we utilized a recently developed selective small molecule PRMT5 inhibitor (PRMT5i, EPZ015666) that has shown in vivo potency in MCL models. To understand the molecular mechanisms of action of PRMT5i in PCa, we performed deep RNA-seq analysis in PC3 and LNCaP cells treated with or without PRMT5i at 4 μM for 4 days in vitro.

2023-12-25 | GSE114151 | GEO

Treatment of LNCaP cells with novel PRMT5:MEP50 protein:protein interaction inhibitors

Project description:We developed a novel compound for inhibition of PRMT5:MEP50 protein:protein interaction. LNCaP prostate cancer cells were treated with Compound 17 for 72 hours. Cells were harvested, RNA isolated, and then submitted for RNA-sequencing,

2025-06-17 | GSE206460 | GEO

shRNA-mediated knockdown of PRMT5 gene in LNCaP cells

Project description:shRNA-mediated knockdown of PRMT5 gene in LNCaP cells

| PRJNA849221 | ENA

PRMT5 regulated transcriptome in prostate cancer cells

Project description:PRMT5 regulated transcriptome in prostate cancer cells

| PRJNA464885 | ENA

Genome-wide analysis of genes regulated by p44/wdr77 and PRMT5 in lung and prostate cancer cells

Project description:Analysis of gene expression in lung and prostate cancer cells expressing non-target (NT), p44/wdr77. or PRMT5 shRNA. Results provide important information on how p44/wdr77 and PRMT5 control cellular proliferation. Total RNA obtained from cells expressing NT, p44/wdr77, or PRMT5 shRNA.

2014-04-14 | E-GEOD-56757 | biostudies-arrayexpress

Fine mapping of androgen regulated genes in LNCaP cells

Project description:Detailed analysis of androgen regulated gene expression in the LNCaP prostate cancer cell line. Since androgens and the AR are known to be important for prostate cancer cell proliferation and invasion we aimed to identify androgen receptor (AR) regulated genes by combining this detailed Illumina beadarray study of androgen regulated gene expression with AR ChIP-sequencing data. LNCaP cells were grown in RPMI medium supplemented with 10% charcoal dextran stripped (steroid depleted) FBS for 72h, before treatment with 1nM R1881 or vehicle control. Total RNA was harvested every 30min for 4h and then every hour up to 24h using trizol (Sigma), quantified using a Nanodrop spectrophotometer (ND-1000). RNA samples were prepared for analysis on Illumina Human 6 v2 BeadArrays and Biotrove Realtime PCR panels according to the manufacturers protocols (see Supplementary Methods for details). Expression array data were normalised in R using the beadarray software and BASH (see Supplementary Methods for details) (Cairns et al., 2008; Dunning et al., 2007).

2010-09-01 | GSE18684 | GEO

Treatment of LNCaP cells with novel PRMT5:MEP50 protein:protein interaction inhibitors

Project description:Treatment of LNCaP cells with novel PRMT5:MEP50 protein:protein interaction inhibitors

| PRJNA851032 | ENA